NEWS

THE STORY BEHIND MANGALAM DRUGS





Targetting Rs 300 cr revenue by FY17: Mangalam Drugs

Speaking to CNBC-TV18 Govardhan Dhoot, MD, Mangalam Drugs, said that margins have improved. Revenue growth is on track and it is looking at Rs 300 crore of revenue by end of FY17. We are Hoping for a 10-15 percent growth, he said. “We are focussing on the topline.”


HOPE TO MAINTAIN RS 80CR QUARTERLY REVENUE RUN RATE: MANGALAM



Midcap Radar: Govardhan Dhoot MD, Mangalam Drugs

Mangalam Drugs is the worlds largest manufacturer of anti-malarial APIs, Reema Tendulkar and Mangalam Maloo discuss more about with company and its growth outlook for FY16 with Govardhan Dhoot Managing Director of the company

Mangalam Drugs sees 30-40% growth in topline for FY12

In an interview with CNBC-TV18, Govardhan Dhoot, MD, Mangalam Drugs Organic, spoke about the latest happenings in his company and the road ahead.